Stock PPBT PURPLE BIOTECH LTD.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Highlights Purple Biotech Ltd. TEL AVIV STOCK EXCHANGE

Equities

PPBT

IL0007650166

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Purple Biotech Says Interim Data from Pancreatic Cancer Drug Study Shows Promise
MT
Purple Biotech Ltd. Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival Benefit
CI
Purple Biotech Ltd Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and Other Efficacy Endpoints in Pancreatic Cancer
CI
Purple Biotech Ltd.'s Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual Meeting
CI
Purple Biotech Reports Preclinical Proof of Concept for Its Tribody Platform Technology
CI
Purple Biotech Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Purple Biotech Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
CI
Purple Biotech Presents Data of Its Phase 1 Head & Neck Cancer of NT219 in Combination with Cetuximab At ESMO TAT Congress 2024
CI
Purple Biotech Reaches Recommended Phase 2 Dose for NT219
CI
Purple Biotech Ltd. Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial
CI
Purple Biotech Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Purple Biotech Reports Potential Biomarker Data Support CM24?s Mechanism of Action
CI
Purple Biotech Ltd. Reports Positive Interim and Preliminary Results from NT219 Phase 1/2 Study in R/M Head & Neck Cancer
CI
Purple Biotech Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Purple Biotech Ltd. Reports Positive Results of CM24 Dose Escalation in Advanced Pancreatic Cancer Patients
CI
Purple Biotech Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Kitov Pharmaceuticals Holdings Ltd. Submits New Drug Application to FDA for KIT-302
CI
Kitov Pharmaceuticals Holdings Ltd. Announces Results of Study Demonstrating NT-219 Enhanced Efficacy of Keytruda® in Immune-Oncology Preclinical Model
CI
Kitov Pharmaceuticals Holdings Ltd. Provides Updates on KIT-302 New Drug Application
CI
U.S. Food and Drug Administration Grants Kitov Pharmaceuticals Holdings Ltd for New Drug Application Filing Fee
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PPBT Stock
  4. PPBT Stock
  5. News Purple Biotech Ltd.
  6. Highlights